Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 plus immunosuppressive therapy for aplastic anemia (observational)
ChiCTR2500111349Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: 24-week overall hematologic response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2500111349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111349.